Karen Flynn
2021
In 2021, Karen Flynn earned a total compensation of $1.8M as President, Biologics & Chief Commercial Officer at Catalent, a 33% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $558,640 |
|---|---|
| Option Awards | $195,002 |
| Salary | $533,457 |
| Stock Awards | $455,156 |
| Other | $54,425 |
| Total | $1,796,680 |
Flynn received $558.6K in non-equity incentive plan, accounting for 31% of the total pay in 2021.
Flynn also received $195K in option awards, $533.5K in salary, $455.2K in stock awards and $54.4K in other compensation.
Rankings
In 2021, Karen Flynn's compensation ranked 6,463rd out of 12,415 executives tracked by ExecPay. In other words, Flynn earned more than 47.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,463 out of 12,415 | 48th |
Division Manufacturing | 2,768 out of 5,505 | 50th |
Major group Chemicals And Allied Products | 1,222 out of 2,375 | 49th |
Industry group Drugs | 1,090 out of 2,096 | 48th |
Industry Pharmaceutical Preparations | 790 out of 1,546 | 49th |
Pay ratio
| Karen Flynn's Pay | $1,796,680 |
|---|---|
| Median Employee's Pay | $61,477 |
| Pay Ratio | 29to 1 |
In 2021, the annual total compensation of Karen Flynn was $1,796,680.
The annual total compensation of the median employee at Catalent was $61,477.
The ratio of Karen Flynn's pay to the pay of median employee was therefore 29 to one.
Source: SEC filing on September 17, 2021.
Flynn's colleagues
We found five more compensation records of executives who worked with Karen Flynn at Catalent in 2021.